Selank

Selank is a synthetic, tuftsin-derived heptapeptide. The sequence identified in the cited publisher abstract is Thr–Lys–Pro–Arg–Pro–Gly–Pro (TKPRPGP).

Products are not interchangeable. The manufacturer-hosted Peptogen label describes over-the-counter nasal drops in Russia; that product information is not evidence of US FDA approval, a prescription Selank spray, or equivalent concentration for another spray or injectable preparation.

Human symptom studies, imaging experiments, animal models and molecular studies answer different questions. The sections below keep those evidence types separate rather than treating a proposed mechanism or product label as a clinical outcome.

Proposed mechanisms include effects on GABA-related signaling, stress responses and immune markers. In a 2016 rat study, 30 male Wistar rats received intranasal Selank, GABA or control exposure. Frontal-cortex tissue was pooled by group and time, with technical PCR repeats. The expression pattern supports a GABA-system hypothesis, not established selective receptor action, a human neurotransmitter increase, clinical onset or healthy-cognition benefit.

BDNF findings are model-specific. In a 2019 ethanol-exposure rat study, seven days of intraperitoneal Selank prevented an ethanol-associated BDNF increase in the reported model. An indexed 2008 rat hippocampal paper examines BDNF expression, adding another molecular research direction. These model-specific findings do not establish a universal BDNF or neurotransmitter increase.

These mechanistic studies help explain the interest in Selank beyond anxiety. Their clinical relevance depends on separately measuring outcomes in people.

The clearest human signal is limited anxiety research. A 2008 PubMed abstract describes 62 patients with generalized anxiety disorder or neurasthenia, compares Selank with medazepam, and reports Hamilton, Zung and CGI measures. The authors report similar anxiolysis and antiasthenic or psychostimulant observations. This is a positive signal, not formal equivalence, superiority or evidence for a general dose.

A 2014 comparative abstract involving 60 patients with phobic-anxiety or somatoform disorders reports pronounced anxiolytic and mild nootropic effects for Selank compared with phenazepam. That population, comparator and abstract endpoint do not establish a general cognition regimen, social-performance protocol or long-term safety program.

In a 2020 imaging study, 52 healthy participants were assigned to separate Semax, Selank and placebo groups. Resting-state functional connectivity was measured at baseline, 5 minutes and 20 minutes. Connectivity is an imaging endpoint, not demonstrated memory, attention or work-performance improvement, and separate groups do not test a combined Semax–Selank regimen.

A conference abstract describes 20 people with generalized anxiety disorder receiving 2,700 mcg/day intranasally. It reports 40% rapid responders and 60% gradual responders, with Hamilton Anxiety Rating Scale improvement during days 1–3 for the rapid group and by day 14 for the gradual group. The abstract does not describe a control group; these percentages describe response timing, not symptom reduction or a personal schedule.

A 2019 report involved 55 patients with mixed anxiety-depression or moderate depression with anxiety. All received escitalopram; Selank was added during the first two weeks for 35 people, while 20 received escitalopram alone. MADRS and HAM-A were assessed at two and four weeks, and the authors reported faster mood and anxiety improvement with the adjunct group. This is preliminary adjunct evidence, not Selank-alone efficacy or SSRI superiority.

Cognition remains an emerging area. The 2019 rat study reported a cognitive-stimulating effect in an object-recognition test in 9-month-old rats and protection against memory and attention disturbances during ethanol withdrawal. Those positive animal findings do not establish improved memory or dementia prevention in people.

The 2008 immune-marker abstract reports reduced IL-6 gene expression in cells from patients with depression in vitro but an increased IL-6 concentration in the culture medium. A 14-day in-vivo component involving people with generalized anxiety disorder or neurasthenia describes changes in the balance of Th1 and Th2 cytokines. These are biological markers, not measured prevention of infection or treatment of an inflammatory disease.

Anecdotal accounts may describe feeling calmer while remaining alert, but they cannot establish how often a benefit or side effect occurs. The cited record does not establish a reliable social- or performance-anxiety benefit, a universal cognitive benefit or treatment of an inflammatory disease.

No established general Selank dosage protocol is supported by the evidence summarized here. The 2,700 mcg/day amount in the conference abstract is study context for 20 people with generalized anxiety disorder, not a universal regimen or instruction for self-administration.

The Peptogen label describes Russian over-the-counter nasal drops containing 1.5 mg/mL Selank diacetate. For that named product, the label specifies two drops in each nostril three times daily for 14 days, with a possible repeat after 1–3 weeks following physician consultation. The drop volume is not established here, so the concentration cannot be converted into mcg per drop. That label-specific product should not be treated as interchangeable with another spray, solution or injectable preparation.

Onset, duration, exposure and tolerability may vary by formulation, route, dose and the person’s other medicines. The available record is not a basis for choosing a personal dose, changing prescribed treatment or assuming that one product’s instructions apply to another.

The available record includes small human studies, product-label statements and animal experiments, not a years-long comparative safety program. The FDA compounding information lists Selank acetate among nominated-but-withdrawn substances and discusses missing safety information plus potential immunogenicity or aggregation concerns for some compounded routes. This is regulatory and formulation-risk context, not a blanket legal conclusion or proof that every reported research finding is false.

The Peptogen label is specific to its nasal-drop product: it lists unpleasant taste and possible allergic reactions and restricts use during pregnancy, breastfeeding and under age 18. They provide product-specific safety information, not a complete risk profile for other preparations.

The small studies discussed here do not establish no interactions, no tolerance, no dependence, no withdrawal or indefinite safety across formulations. Do not replace, taper or combine prescribed medicines on the strength of these limited findings.

A 2015 adjunct study compared 30 patients receiving phenazepam with 40 receiving phenazepam plus Selank in anxiety-phobic, hypochondriac or somatoform disorders. The abstract reports earlier therapeutic benefit and fewer phenazepam-associated adverse effects, including sedation and attention or memory problems. This is a positive combination-treatment finding, not proof of zero adverse effects, Selank-alone superiority or a general stacking protocol.

The 2019 escitalopram report likewise studied Selank as an add-on, not as an SSRI replacement. The combination was assessed in a specific small study and should not be generalized to other medicines or patients.

Semax–Selank use remains anecdotal in this record. The 2020 imaging study used separate Semax, Selank and placebo groups, not a combined regimen. No evidence summarized here establishes synergy with Semax, L-theanine, thymosin alpha-1, Dihexa or caffeine, or rules out medication interactions.